Comparative Pharmacology
Head-to-head clinical analysis: AMOXICILLIN PEDIATRIC versus LAROTID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMOXICILLIN PEDIATRIC versus LAROTID.
AMOXICILLIN PEDIATRIC vs LAROTID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin is a semisynthetic penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). It blocks the transpeptidation step in peptidoglycan cross-linking, leading to cell lysis and death.
Larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) A, B, and C. It inhibits TRK kinase activity by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways, which results in reduced cell proliferation and tumor growth in tumors with NTRK gene fusions.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours for adults.
Larotrectinib 100 mg orally twice daily, with or without food, for adult patients.
None Documented
None Documented
Terminal elimination half-life: 1-1.5 hours in children with normal renal function; prolonged to 7-21 hours in anuria.
30 minutes; prolonged in renal impairment (up to 20 hours in anuria).
Renal: 60-80% unchanged via glomerular filtration and tubular secretion; biliary: minor (<10%); fecal: <5%.
Renal: 70-80% unchanged by glomerular filtration and tubular secretion; Biliary/Fecal: <10% as inactive metabolites.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic